EUVIMEDEUVIMED entdecken
Crossref

Intranasal co-delivery of riluzole and berberine via chitosan-coated PLGA nanoparticles for synergistic neuroprotection in Alzheimer’s disease: formulation, characterization, and pharmacokinetics analysis

Mohammed H El Komy, Basmah Nasser Aldosari, Randa Mohammed Zaki, Rawan Bafail, Rehab Mohammad Yusif, Mohamed A Abdelgawad, Mohammed Elmowafy, Ahmad Y Abuhelwa, Hussein M Eid

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026

DOI: 10.1007/s00210-026-05182-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Mohammed H El Komy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, College of Pharmacy, Jouf University, 72341, Sakaka, Saudi Arabia. mhalkomy@ju.edu.sa. Hauptthemen laut MEDLINE: Berberine, Chitosan, Neuroprotective Agents, Riluzole. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 75 Literaturangaben. Gefördert von: Al Jouf University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study presents an intranasal chitosan-coated PLGA nanoparticle system co-loaded with riluzole (RLZ) and berberine (BER) to achieve synergistic neuroprotection and enhanced brain targeting for Alzheimer's disease therapy. Chitosan-coated PLGA nanoparticles containing riluzole and berberine (RLZ-BER-CTS-PLGA) were prepared via a modified single emulsion-solvent evaporation method using 0.9% PLGA and 1% PVA, and 0.99% chitosan. The optimized formulation exhibited a size of 203.5 nm, zeta potential of + 34.7 mV, and high entrapment efficiencies of 73.9% (RLZ) and 71.4% (BER). In vitro release showed sustained delivery, with only 36.3% BER and 28.4% RLZ released after 2 h compared to 82.6% and 57.3% from suspensions. Ex vivo nasal permeation demonstrated 2.8-fold (BER) and 2.1-fold (RLZ) increases in permeability coefficients relative to drug suspensions. Pharmacokinetic evaluation confirmed superior brain delivery, with intranasal RLZ-BER-CTS-PLGA achieving Cmax levels of 596 ng/mL for BER and 1345 ng/mL for RLZ, versus only 213 ng/mL and 385 ng/mL from intranasal suspensions. Direct transport percentage (DTP) reached 81.4% for BER and 56.4% for RLZ, with corresponding drug targeting efficiencies (DTE) of 536.6% and 229.3%. Histopathology confirmed nasal safety with no mucosal irritation. These results establish chitosan-functionalized PLGA nanocarriers as a promising noninvasive co-delivery platform for multifunctional Alzheimer's therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BerberineChitosanNeuroprotective AgentsRiluzoleAlzheimer DiseaseNanoparticlesAnimalsAdministration, IntranasalPolylactic Acid-Polyglycolic Acid CopolymerMaleBrainRats, Sprague-DawleyDrug LiberationDrug Carriers

Stichwörter der Autor:innen

Alzheimer’s disease therapyBerberineBrain targetingChitosan-coated PLGA nanoparticlesIntranasal drug deliveryRiluzole

Substanzen

BerberineChitosanPolylactic Acid-Polyglycolic Acid CopolymerNeuroprotective AgentsRiluzoleDrug Carriers

Autor:innen und Institutionen

  • Department of Pharmaceutics, College of Pharmacy, Jouf University, 72341, Sakaka, Saudi Arabia. mhalkomy@ju.edu.sa.
  • Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, P.O. Box 2457, 11451, Saudi Arabia.
  • Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, P.O. Box 173, 11942, Saudi Arabia.
  • Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, 62511, Egypt.
  • Department of Pharmaceutics and Pharmaceutical Industries, College of Pharmacy, Taibah University, Al-Madinah, Al-Munawarah, P.O. Box 30039, 41477, Saudi Arabia.
  • Department of Pharmaceutics, Faculty of Pharmacy, Mansoura University, Mansoura, P.O. Box 35516, Egypt.

Förderung

  • Al Jouf University

Zitieren

APA

Komy, M. H. E., Aldosari, B. N., Zaki, R. M., Bafail, R., Yusif, R. M., Abdelgawad, M. A., Elmowafy, M., Abuhelwa, A. Y., & Eid, H. M. (2026). Intranasal co-delivery of riluzole and berberine via chitosan-coated PLGA nanoparticles for synergistic neuroprotection in Alzheimer’s disease: formulation, characterization, and pharmacokinetics analysis. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-05182-3

Vancouver

Komy MHE, Aldosari BN, Zaki RM, Bafail R, Yusif RM, Abdelgawad MA, et al. Intranasal co-delivery of riluzole and berberine via chitosan-coated PLGA nanoparticles for synergistic neuroprotection in Alzheimer’s disease: formulation, characterization, and pharmacokinetics analysis. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-05182-3

BibTeX
@article{Komy2026,
  author = {Komy, Mohammed H El and Aldosari, Basmah Nasser and Zaki, Randa Mohammed and Bafail, Rawan and Yusif, Rehab Mohammad and Abdelgawad, Mohamed A and Elmowafy, Mohammed and Abuhelwa, Ahmad Y and Eid, Hussein M},
  title = {Intranasal co-delivery of riluzole and berberine via chitosan-coated PLGA nanoparticles for synergistic neuroprotection in Alzheimer’s disease: formulation, characterization, and pharmacokinetics analysis},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-026-05182-3}
}
Kostenlos starten →